The IRS is proposing to remove regulations that tried to crack down on the abusive use of basis-shifting transactions by partnerships as a way of minimizing taxes.
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
In the future of finance, the success of AI tools won’t depend on scattered individual initiatives, but on establishing a standardized approach across teams.